PHARMACOLOGICAL REVIEWS
PHARMACOLOGICAL REVIEWS(英文缩写 PHARMACOL REV),ISSN 0031-6997,eISSN 1521-0081 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-21 至 2026-09-21，按本站收录文献的发表日期统计。
指标来源：jcr_cas_ifqb
期刊简介
暂无简介。
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 20.479 | Q1 |
| 2022 | 21.100 | Q1 |
| 2023 | 19.300 | Q1 |
| 2024 | 17.300 | Q1 |
| 2025 | 20.300 | Q1 |
PHARMACOLOGICAL REVIEWS 最新收录文献
※ 中文译文由 AI 辅助生成,仅供学术参考,请以英文原文为准。
-
1. Hunting gremlins: GREM1 as a new therapeutic target for multiple diseases including glaucoma.
PMID:作者:日期:2026-07-15The transforming growth factor-β (TGF-β) superfamily of signaling molecules is involved in normal development and homeostasis. However, aberrant signaling among members of the TGF-β superfamily plays an important pathogenic role in numerous diseases. Increased expression of the pleiotropic cytokine …
-
2. Aryl hydrocarbon receptor pharmacology-mechanisms, ligands, and therapeutic potential.
2. 芳香烃受体药理学机制、配体和治疗潜力PMID:作者:日期:2026-07-01The aryl hydrocarbon receptor (AHR) is a ligand activated transcription factor that has emerged as a key modulator of several physiological and pathological processes. Historically, AHR has been studied for its role as a mediator of the toxic responses of environmental pollutants, such as 2,3,7,8-te…
-
3. Mitochondrial metabolism as a pharmacological target for cancer therapeutics.
PMID:作者:日期:2026-07-01Mitochondria are essential cellular organelles that were first identified in the mid-19th century. Despite more than 150 years of research and the accumulation of vast wealth of knowledge on mitochondrial structure and functions, new breakthroughs are still being made in recent years in key areas of…
-
5. Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases.
PMID:作者:日期:2026-06-26Peptide hormones play a central role in maintaining metabolic homeostasis by integrating complex signaling pathways to coordinate interorgan crosstalk. Aberrant production and/or dysfunction of peptide hormones are important contributors to the pathophysiology of a cluster of interrelated chronic me…
-
6. Chronic pain in Alzheimer disease and the role of neuroimmune interactions.
PMID:作者:日期:2026-06-26Chronic pain conditions affect a large proportion of the global population and pain has tremendous personal and economic impact, affecting quality of life and ability to work while imposing a significant burden on families and health care systems. Neurological disorders and painful conditions are fr…
-
7. Exploration of multifunctional characteristics and regulatory mechanism of promoter G-quadruplexes.
PMID:作者:日期:2026-06-26G-quadruplexes (G4s), a specialized nucleic acid secondary structure, have been found in recent years to be widely distributed in gene promoter regions. Growing evidence has highlighted the significance of G4 structures of promoter region in regulating various biological processes, including transcr…
-
8. Renal aging and associated diseases: Common mechanisms and therapeutic approaches.
PMID:作者:日期:2026-06-19The kidneys are highly metabolically active organs that undergo a progressive, intrinsic decline in renal function with aging, a process that can be further exacerbated by chronic exposure to oxidative stress, inflammation, hypertension, and various toxins. Studies have shown that the prevalence of …
-
9. Recent advances in methotrexate pharmacology and potential therapeutic uses in age-related cardiometabolic and neurodegenerative diseases.
PMID:作者:日期:2026-06-12Experimental and clinical evidence continues to accumulate, supporting the critical role of dysregulated inflammation, immunity, and redox signaling in the pathophysiology of various age-related cardiometabolic and neurodegenerative diseases. While ongoing research is investigating novel anti-inflam…
-
10. Translational medications development for methamphetamine use disorder: A systematic review of preclinical, human laboratory, and clinical research.
PMID:作者:日期:2026-05-27The prevalence of methamphetamine use disorder (MUD) remains discouragingly high. Relatively few clinical trials have focused on identifying new pharmacotherapies for MUD, and no medications have received US Food and Drug Administration approval. The lack of available pharmacotherapies may be due to…